Daktari Biotechnology Limited (herein referred as "the company", "our", "we") is an innovation-led organization that aims to enable and provide access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
The company is engaged in developing high quality, affordable biosimilars aimed at expanding patient access to a cutting-edge class of therapies. It is our goal to grow into a fully integrated biosimilars organization which will become an independent division of the company. We aspires to transform patient lives through innovative and inclusive healthcare solutions by developing and producing a large portfolio of biosimilars. The company’s goal is to establish product pipeline of at least 15 biosimilars molecules, including insulins, erythropoietin, interferons, VEGF and several others.
We are also committed to developing innovative molecules to address unmet patient needs and its pipeline of promising assets which will include, vaccines and immunotherapy molecules. It is the company’s goal to successfully launch a couple of therapeutics in Kenya after the opening of Daktari Biotechnology R&D and the manufacturing facilities.
Our plans is to build large scale, manufacturing infrastructure to support its ambition of making an impact on Africa’s medicines supply.
Daktari Biotechnology's passion to impact global health is driven by our goal to develop affordable drugs with the potential to benefit a million patients on the African continent.